Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nano-DC vaccine
- Development stage
- Preclinical
- Lead developer
- Methodist Hospital Research Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
Nano-DC vaccine is an experimental autologous dendritic cell-based cancer vaccine developed by the Houston Methodist Research Institute for the treatment of HER2-positive breast cancer. The vaccine consists of bone marrow-derived dendritic cells (DCs) loaded with porous silicon microparticles (PSMs) that are packaged with HER2 antigen peptides. The PSMs serve a dual role: they act as a reservoir for the sustained release of HER2 antigen peptides to enhance cross-presentation, and they function as a potent adjuvant by stimulating type I interferon (IFN) expression in DCs via the TRIF/MAVS pathways. In preclinical murine models of HER2-positive breast cancer, the Nano-DC vaccine has been shown to activate and expand antigen-specific CD8+ cytotoxic T cells and promote a Th2-to-Th1 transition in the tumor microenvironment, leading to robust anti-tumor activity.
- Other names
- PSM-based therapeutic dendritic cell vaccineporous silicon microparticle-based therapeutic dendritic cell vaccine
02
Targets
MAVS (Mitochondrial antiviral-signaling protein)TRIF (TICAM1)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on Nano-DC vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nano-DC vaccine.